Precision medicine is redefining how we evaluate and treat disease. No longer is cancer defined by its organ of origin, tissue or cell type but rather its genotype.

Conducting traditional 3-phased clinical trials in these orphan disease categories on a myriad of novel therapeutics, while trying to expedite therapies from lab bench to bedside is forcing a transformation of both the clinical development and regulatory process. From cohort expansion to accelerated pathways to decentralized trials, this transformation has placed real-world evidence at the center of the approval process.

We’ll explore how the traditional one-size-fits-all clinical development and regulatory approval paradigm has evolved to become an increasingly customizable process.

 on July 19, 2021, at 12:00 PM EDT for the latest Oncology Value Coalition webinar with Cardinal Health.

The evolution and complexity of FDA regulatory pathways,

The impact of the pandemic on decentralized trial design,

The role real-world evidence will likely play in the future of drug approvals

How all of this sets the stage for understanding Biogen’s approach to Aducanumab


Vice President of Clinical Affairs and Chief Medical Officer
Cardinal Health Specialty Solutions

Vice President and Chief Medical Officer
Cardinal Health Specialty Solutions


Director of Real-World Evidence & Insights
Cardinal Health Specialty Solutions


Director of Real-World Evidence and Regulatory Sciences
Cardinal Health Specialty Solutions

The Evolution of Clinical Research: Expedited Pathways, RWE, and Decentralized Trials

The COVID-19 pandemic has magnified the crucial role of primary care in advancing population health. Payers and providers are collaborating in novel ways to expand access to quality, affordable primary care.

Join 

 on June 21, 2021, at 12:00 PM EDT for the latest Matters in Managed Care webinar featuring experts from Blue Cross and Blue Shield of North Carolina, Duke-Margolis Center for Health Policy, UNC Center for the Business of Health, and WakeMed.

Learn how payers and primary care providers have managed patient needs during this time of change

Gain insight into new opportunities for expanding access to value-based care

Understand the interconnectedness of behavioral/mental health, healthy equity, and primary care


Medical Director, Community Population Health


Vice President, Population Health Management

Blue Cross NC Advanced Primary Care and Value-Based Provider Engagement

Investing in Primary Care: New Collaborations for the Postpandemic Era

Genomic testing has changed the face of cancer care. Using the right test at the right time can ensure more informed decision making by providers and by patients and their families. But designing precision medicine solutions cannot happen if patients lack access to testing, or if tests results are used incorrectly.

's Oncology Value Coalition, will highlight the potential of genomic testing, the opportunities that exist through collaboration between academic centers and the private sector, and the barriers that some patients still face.

Understand how genomic testing is changing the cancer care landscape

Understand how genomics and precision medicine is altering the pipeline for anti-cancer therapeutics

Understand gaps in care that patients face in accessing precision-medicine-based cancer care

Understand how leading academic and clinical centers and new companies in the private sector are improving access to innovative cancer care

 chief clinical advisor, AccessHope; vice president, government affairs and senior medical director for employer strategy, clinical professor, hematology/HCT, City of Hope

 medical director, GI oncology, AccessHope; director, employer strategy, associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope

 executive medical director, AccessHope; associate clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope

Bringing Precision Medicine Solutions to the Cancer Journey

 welcomes leaders from Anthem and a partner of Anthem’s Doula Pilot Program in California, to discuss how a health plan can take an active role in 

 in maternity mortality, which has been recognized by the World Health Organization as a growing health concern in the United States.

Discover Anthem’s approach to addressing maternal birth equity disparities through a successful multi-sector partnership approach.

Learn about Anthem’s Doula Pilot Program in California, including program details such as building community partnerships, innovative payment structures and a review of outcomes.

Hear from a community partner about the value of working directly with a health plan and learn how to get involved locally.

Understand how Anthem is influencing and supporting policy development relating to doula services.

Bringing Equity at Birth: A Health Plan Approach for Reducing Disparities Through Partnerships

Metastatic breast cancer (mBC) remains the leading cause of cancer-related death in women. Chemotherapy remains the backbone of mBC treatment; however, new developments across the therapeutic spectrum are expanding clinical approaches to care. Among chemotherapy agents, efforts are underway to improve delivery mechanisms, efficacy, and toxicity profiles, with a shift towards oral therapy, but how do we balance value, costs and health improvements?

® on December 17 at 3pm and 5 pm ET to gain insights from leaders from West Cancer Center and Stanford Cancer Centers as they discuss the shifting treatment paradigm in mBC and their approach to ensuring success with oral therapy.

Explore unmet treatment needs and innovations in mBC, particularly the developing spectrum of chemotherapeutic interventions

Educate the oncology community on emerging therapies in mBC with an emphasis on oral therapy

Discuss benefits and challenges of oral therapy, including the impact of COVID-19 on uptake

New Pathways and Chemotherapeutic Delivery Mechanisms in the Treatment of Metastatic Breast Cancer

When it comes to controlling health care spending, we need to allocate scarce resources based upon what brings the greatest value to patients and our health care system. Recent studies that examined health care improvements in life expectancy and patient well-being over 20 years found that spending in 2 areas often maligned for their costs—biopharmaceuticals and public health—account for much of those improvements. How do we balance value, costs and health improvements?

In this webinar, gain insights from leaders from National Pharmaceutical Council, Harvard University, and Blue Cross Blue Shield of Michigan as they discuss the studies and dive deeper into the implications of health spending on public health efforts and pharmaceuticals.


Interim President and CEO
National Pharmaceutical Council


Clinical Pharmacy Manager, Medicare Pharmacy Services
Blue Cross Blue Shield of Michigan


PhD Candidate, Program in Health Policy, Harvard University


Vice President of Research
National Pharmaceutical Council


Otto Eckstein Professor of Applied Economics
Harvard University

Webinars